This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the
treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).
One of the main ways cancer is able to develop is by hiding or evading our immune system
which usually detects and kills potential tumor cells. Once cancer has developed the ability
to evade the immune system it can continue to grow and become a tumor. One potential strategy
currently being researched, called immunotherapy, uses viruses to stimulate an immune
response which attacks the tumor.
Imvamune is a live, non-replicating virus used in Canada to vaccinate adults and children
against smallpox. It is safe to use in immunosuppressed patients because the virus is unable
to replicate and spread past the first infected cell. This makes the Imvamune vaccine a
viable candidate for immunotherapy in immunosuppressed patients who are at a much higher (up
to 60x) risk of developing non-melanoma skin cancers.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.